Konstanty Korski
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Immunotherapy and Immune Responses, Radiomics and Machine Learning in Medical Imaging, AI in cancer detection
Most-Cited Works
- → Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors(2017)785 cited
- → Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research(2017)706 cited
- → Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma(2016)702 cited
- → The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation(2020)277 cited
- → The molecular basis of breast cancer pathological phenotypes(2016)111 cited
- → Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade(2022)96 cited
- → TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development(2016)82 cited
- → Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients(2020)72 cited
- → Immune contexture of paediatric cancers(2022)48 cited
- Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.(2008)